Swiss-German biotech Vaximm is teaming up with Tokyo-based AI specialist NEC to advance personalised neoantigen cancer vaccines.

Expedeon has sold its immunology and proteomics business activities to global life sciences company Abcam. Abcam is paying €120m in cash for the business.

Fibra-Cel® Disks are an advanced, solid support material for the efficient growth of mammalian and insect cells in bioreactors. They are devised to improve the cultivation of anchorage-dependent as well as suspension cells. Fibra-Cel Disks can be used also for perfusion cell culture with the Eppendorf packed-bed impeller – available for glass, stainless steel, and single-use bioreactors.

Autoimmunity specialist SciRhom GmbH has kicked of a first-in-class antibody development programme targeting iRhom2.

Nosopharm, a company dedicated to the research and development of new anti-infective drugs, has named Jacques Biton as its new chairman of the board, taking over from Gilles Alberici.

At the CPhI Worldwide in Frankfurt, the winners of the 2019 Pharma awards were announced. The CEO of WuXi AppTec, Dr. Ge Li, received the award in category CEO of the year among 12 other categories.

A drug combo breaking antibiotic resistance of Gram-negative priority pathogens has been selected under the ENABLE programme of the Innovative Medicines Initiative (IMI).

Swiss specialty pharmaceutical company Santhera has named Dario Eklund as new CEO. Eklund joins from Vifor Pharma, where he served as Chief Commercial Officer.

Bergen Bio ASA’s Axl kinase blocker bemcentinib in combination with MSD’s pembrolizumab has met the primary endpoint in a Phase II study in patients with non small cell lung cancer (NSCLC).

German researchers have designed a modified Sleeping Beauty transposase that can be used for non-viral, stable and efficient gene insertions for gene and CAR-T therapies.